Cantor Fitzgerald Predicts TVTX FY2026 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Travere Therapeutics in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal expects that the company will post earnings per share of $1.86 for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($1.40) per share.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.08. Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The company had revenue of $81.73 million for the quarter, compared to the consensus estimate of $77.44 million. During the same quarter in the previous year, the business earned ($1.76) EPS. The company’s quarterly revenue was up 83.3% compared to the same quarter last year.

A number of other analysts also recently commented on the stock. Wedbush reiterated an “outperform” rating and issued a $30.00 target price on shares of Travere Therapeutics in a report on Friday, May 16th. Citigroup dropped their price target on Travere Therapeutics from $35.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday. Stifel Nicolaus raised their price objective on Travere Therapeutics from $22.00 to $23.00 and gave the stock a “hold” rating in a research note on Friday, May 2nd. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Travere Therapeutics in a research report on Wednesday. Finally, Scotiabank reaffirmed an “outperform” rating on shares of Travere Therapeutics in a report on Friday, April 11th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $32.14.

Travere Therapeutics Price Performance

Shares of Travere Therapeutics stock opened at $15.13 on Wednesday. Travere Therapeutics has a 52 week low of $6.80 and a 52 week high of $25.29. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The stock has a market cap of $1.34 billion, a PE ratio of -3.69 and a beta of 0.75. The company’s 50-day moving average price is $16.88 and its two-hundred day moving average price is $18.61.

Institutional Trading of Travere Therapeutics

Institutional investors have recently bought and sold shares of the company. Entropy Technologies LP acquired a new position in Travere Therapeutics in the 4th quarter worth about $214,000. US Bancorp DE grew its stake in shares of Travere Therapeutics by 323.4% in the 4th quarter. US Bancorp DE now owns 31,795 shares of the company’s stock valued at $554,000 after buying an additional 24,286 shares in the last quarter. Northern Trust Corp increased its holdings in Travere Therapeutics by 11.3% in the fourth quarter. Northern Trust Corp now owns 754,395 shares of the company’s stock worth $13,142,000 after buying an additional 76,358 shares during the last quarter. Swiss National Bank raised its position in Travere Therapeutics by 12.8% during the fourth quarter. Swiss National Bank now owns 151,900 shares of the company’s stock valued at $2,646,000 after acquiring an additional 17,200 shares in the last quarter. Finally, Wellington Management Group LLP bought a new position in Travere Therapeutics during the fourth quarter valued at approximately $583,000.

Insider Activity at Travere Therapeutics

In other Travere Therapeutics news, CFO Christopher R. Cline sold 1,784 shares of Travere Therapeutics stock in a transaction on Monday, May 5th. The shares were sold at an average price of $21.05, for a total transaction of $37,553.20. Following the completion of the sale, the chief financial officer now owns 93,126 shares of the company’s stock, valued at $1,960,302.30. This trade represents a 1.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Eric M. Dube sold 18,924 shares of the business’s stock in a transaction on Monday, May 5th. The shares were sold at an average price of $21.05, for a total transaction of $398,350.20. Following the transaction, the chief executive officer now owns 419,173 shares in the company, valued at approximately $8,823,591.65. This represents a 4.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,527 shares of company stock valued at $473,814. Company insiders own 4.19% of the company’s stock.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.